Research Article
The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Table 2
Quality assessment and prognostic information of the included studies.
| | Author | Year | Method | Outcome | HR (95% CI) for OS | HR (95% CI) for PFS | Analysis | NOS score |
| | Chalabi et al. [30] | 2020 | RE | OS/PFS | 1.45 (1.20–1.75) | 1.30 (1.10–1.53) | NA | 8 | | Hakozaki et al. [31] | 2019 | RE | OS | 1.90 (0.80–4.51) | NA | M | 6 | | Svaton et al. [32] | 2020 | RE | OS/PFS | 1.22 (0.72–2.05) | 1.36 (0.89–2.06) | M | 8 | | Zhao et al. [33] | 2019 | RE | OS/PFS | 0.68 (0.33–1.43) | 0.91 (0.54–1.54) | U | 8 | | Stokes et al. [34] | 2021 | RE | OS | 0.96 (0.89–1.04) | NA | M | 7 | | Miura et al. [35] | 2021 | RE | OS | 1.36 (0.96–1.91) | NA | M | 7 | | Cortellini et al. [36] | 2021 | RE | OS/PFS | 1.51 (1.28–1.80) | 1.36 (1.17–1.59) | U | 8 | | Giordan et al. [29] | 2021 | RE | OS/PFS | 1.89 (1.23–2.90) | 1.51 (1.11–2.05) | M | 7 | | Hopkins et al. [37] | 2022 | RE | OS/PFS | 1.53 (1.21–1.95) | 1.34 (1.12–1.61) | U | 7 | | Hopkins et al. [38] | 2022 | RE | OS/PFS | 1.00 (0.85–1.17) | 0.93 (0.76–1.13) | U | 8 | | Husain et al. [39] | 2021 | RE | OS | 1.43 (1.06–1.92) | NA | U | 6 |
|
|
OS, overall survival; PFS, progression-free survival; HR, hazard ratio, NA, not available; U, univariate; M, multivariate; NOS, Newcastle-Ottawa Scale; RE, retrospective.
|
